Back to search

Article

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices

2024-05-13

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Hepatitis C virus (HCV) infection affects 58 million people worldwide with around 290,000 deaths annually, mainly due to complications such as cirrhosis and hepatocellular carcinoma (HCC). Portal hypertension (PH) caused by cirrhosis leads to severe consequences, including esophageal varices (EV). To evaluate the effectiveness and safety of DAA treatment in patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3e84df6f-da02-5f4d-bcba-c4c7799aa862
DOI
10.21203/rs.3.rs-4363531/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varicesDOI 10.21203/rs.3.rs-4363531/v1
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.Semantic proximity
Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity
High incidence of hepatocarcinoma in patients with advanced fibrosis treated with direct-acting antiviral agents for hepatitis C: A real-world retrospective study.Semantic proximity
Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Semantic proximity
Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.Semantic proximity
Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.Semantic proximity
Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity
Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in TaiwanSemantic proximity
Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.